CD274 and neoplasm: It is remarkable that the combination treatment of anti‐RGMb and PD‐L1 in the early stage also elevated T cells' pro‐inflammatory cytokine expression, indicating anti‐RGMb could increase T cells' anti‐tumor immunity.